nal von minden: Did my vaccine work? New rapid test for the determination of vaccination success.
25.5.2021 11:46:53 CEST | news aktuell GmbH | Press release

(Moers, Germany): “People want clarity once they been vaccinated against coronavirus: They want to know if it has worked“ says Thomas Zander, CEO of nal von minden GmbH. Depending on the particular vaccine used, the COVID-19 vaccines offer 70% or more protection from the disease – but not 100%.
If the vaccine has ‘worked’, the body produces human antibodies against the disease. “These antibodies ensure that, in the event of exposure, the disease pathogens – the coronaviruses – would be readily identified and quickly repelled. Rather like the police on alert.”
These antibodies can be found in human blood and, if present, are easily detectable. With the NADAL® COVID-19 S1-NAb Test, the process takes just a few minutes. Thomas Zander explains: “Our new rapid test for the detection of coronavirus antibodies can be carried out by your GP in the future, as the test is currently only for professional use. A tiny prick of the finger is enough. The little drop of blood is added to the accompanying test cassette, and results can be read within 15 minutes.”
The new rapid test has already been comprehensively studied in the USA and China. “In the USA and China the vaccination programmes are more progressed, so the first studies were carried out there,” says Zander. “Further quality studies at German research centres will follow shortly.” It has been confirmed that the antibody test works for all kinds of vaccines (BioNtech, AstraZeneca, Johnson&Johnson, Sinovac and Moderna).
Coronavirus vaccinations usually take place across two appointments, and the new rapid test can be carried out either two weeks after the first vaccination, or two weeks after the second, says Thomas Zander. “Those who produce an immune response following the first vaccine – which can cause, for example, mild cold-like symptoms – can first wait until after the second vaccination.” Of course, the test can also be carried out weeks or even months afterwards, as nobody yet knows how long the vaccinations protect us against coronaviruses.
Contacts
Gabriele Hellwig, info@hellwig-pr.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Sustainable Business: The Companies of Schwarz Group Present Roadmap to Combat Climate Risks and Resource Scarcity22.7.2026 09:53:15 CEST | Press release
Seventh Sustainability Report highlights expansion of energy and resource sovereignty External ESG rating confirms effective alignment of sustainability with strategic risk management Climate transition plan serves as central instrument for future-proofing business processes
Battery electric vehicle prices fell 18% and model choice quadrupled between 2020 and 202520.7.2026 06:00:00 CEST | Press release
New study analyzes EV purchase prices and market trends in Germany, Europe's largest car market
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:42:31 CEST | Press release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

